The FDA approved Eli Lilly's Zepbound (tirzepatide) for chronic weight management on November 8, 2023, for adults with a BMI of 30 or greater.

The U.S. Food and Drug Administration approved Zepbound (tirzepatide) for chronic weight management on November 8, 2023. The approval applies to adults with obesity, defined in the FDA announcement as a BMI of 30 kilograms per square meter or greater. The FDA’s approval package and approval letter document the underlying regulatory action.fda.govfda.govFDA Approves New Medication for Chronic Weight Managementaccessdata.fda.govaccessdata.fda.govNDA 217806 NDA APPROVAL Eli Lilly and Company Attention: Ingrid Hensley, PhD+1 more

The claim accurately states the date, drug, manufacturer, active ingredient and BMI threshold for the obesity indication. The full indication is broader than the claim suggests: Zepbound is also approved for adults who are overweight, with a BMI of at least 27, when they have at least one weight-related medical condition. Treatment is intended to be used alongside a reduced-calorie diet and increased physical activity. The omitted indication does not make the narrower statement that adults with a BMI of 30 or greater were covered by the approval inaccurate.accessdata.fda.govaccessdata.fda.govZEPBOUND (tirzepatide) injection, for subcutaneous useinvestor.lilly.cominvestor.lilly.comFDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a...+1 more

The later 2026 label and PharmExec summary describe the same approved population and do not conflict with the contemporaneous November 2023 FDA and Eli Lilly records. The evidence therefore supports the claim as written, while the additional overweight indication provides useful context about the approval’s full scope.investor.lilly.cominvestor.lilly.comZepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living...pharmexec.compharmexec.comFDA Approves Zepbound for Chronic Weight Management+2 more